BMY•benzinga•
Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval For Bristol Myers Squibb's Repotrectinib For Adult Patients With Ros1-positive Advanced Non-small Cell Lung Cancer And Adult And Pediatric Patients Wi
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga